Premium
Panel discussion: DIAN‐TU trial collaborative effort
Author(s) -
Bateman Randall J.,
Ryan Laurie M.,
Carrillo Maria C.,
Kerchner Geoffrey A.,
Farlow Martin R.,
Salloway Stephen P.,
Yaari Roy
Publication year - 2020
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.041133
Subject(s) - clinical trial , medicine , panel discussion , family medicine , library science , gerontology , oncology , psychology , philosophy , linguistics , computer science
Background Dr. Bateman is principal investigator of a therapeutic trial evaluating two investigational drugs, gantenerumab and solanezumab, for dominantly inherited Alzheimer’s disease. Washington University is also the regulatory sponsor for this trial. Funding for DIAN‐TU clinical trials includes the National Institute on Aging of the National Institutes of Health, Alzheimer's Association, Eli Lilly and Co, Hoffman La‐Roche/Genentech, Janssen, Avid Radiopharmaceuticals, GHR Foundation, and an anonymous foundation. Discussion session with leaders from the collaborative group: Randall Bateman (DIAN‐TU, PI), Laurie Ryan (NIH/NIA), Maria Carrillo (Alzheimer’s Association), John Sims (Eli Lilly and Co.), Geoff Kerchner (F. Hoffman‐La‐Roche, Ltd.), Marty Farlow (DIAN‐TU Project Arm Leader, Sola), and Steve Salloway (DIAN‐TU Project Arm Leader, Gant). Trial results discussed.